Why aren’t venture capitalists investing in mental illness?
Academics still haven’t cracked the molecular code to understand what, on a basic science level, […]
View ArticleAre exceptionally creative people on the genetic verge of having a mental...
A new study suggests that there is often a clear genetic link between people who are creative and those who develop a psychiatric disorder.
View ArticleA brain-training game could improve cognition problems in schizophrenia patients
Drugs might not necessarily be the answer to improve conditions for patients with schizophrenia.
View ArticleA hormonal nasal spray could provide health benefits to those with mental...
A new hormonal medication appears to be more effective if used intranasally instead of orally and intravenously, at least for some medical conditions.
View ArticleAlkermes gets FDA approval for monthly schizophrenia drug
Schizophrenia medication treatment could become easier and more effective with Alkermes’ FDA approval for Aristada.
View ArticleMemotext launches spinoff A4i that will call J&J’s Toronto innovation lab home
Memotext also embarked on a deal with Centre for Addiction and Mental Health in Canada to develop and commercialize a mobile health intervention for people with schizophrenia.
View ArticleClik here to view.
Hopkins, Salk seek new treatments for schizophrenia, bipolar disorder
The consortium will use induced pluripotent stem cell (iPSC) technology — a type of stem cell that can be generated from adult stem cells — to find better treatments for the two psychiatric conditions.
View ArticleClik here to view.
Novartis teams up with Pear Therapeutics to develop digital therapeutics for...
Pear Therapeutics Chief Medical Officer Yuri Maricich emphasized that the products Pear is developing with Novartis are intended to do more than support adherence.
View ArticleClik here to view.
Karuna Pharmaceuticals raises $42 million in Series A funding round
The company plans to use the financing to support development of its drug, KarXT, in schizophrenia and indications like pain.
View ArticleClik here to view.
System1 Biosciences raises $25M in Series A round for neurotherapeutics...
System1 Biosciences’ platform combines stem cell lines from patients with brain diseases with a three-dimensional in vitro system and data analytics.
View ArticleClik here to view.
Otsuka, Proteus expand agreement around digital medicines
Otsuka also made an $88 million investment as part of the expansion. The companies plan to launch Abilify MyCite, approved in November 2017, by the end of this year.
View ArticleClik here to view.
Bain invests $350M in new company Cerevel to develop Pfizer’s neuroscience...
Cerevel will take on several clinical and preclinical candidates from Pfizer, which divested from neuroscience this year and will take a 25 percent stake in the new company.
View ArticleClik here to view.
Alkermes’ schizophrenia drug shows lower weight gain than comparator
The company plans to file a New Drug Application next year. An analyst wrote that it’s unclear if the drug will require review by an advisory committee.
View ArticleClik here to view.
Acadia Pharmaceuticals drug flops in Phase III schizophrenia study
Nuplazid, which is FDA-approved for Parkinson’s psychosis, failed to fully improve symptoms as an adjunctive treatment for schizophrenia.
View ArticleClik here to view.
Intra-Cellular share price drops after FDA cancels expert panel meeting for...
The company said the decision to cancel the advisory committee meeting for lumateperone was made so the agency would have additional time to review information the firm had provided regarding the drug.
View ArticleClik here to view.
Bouncing back from FDA rejection, Alkermes psychiatric drug wins approval
Alkermes antipsychotic drug Lybalvi now has FDA approval. Though the field of neuropsychiatric drugs is crowded with generic medications, Alkermes believes Lybalvi, designed to mitigate the weight gain...
View ArticleClik here to view.
The emerging golden era of neuroscience [Sponsored]
Bill Martin, the Global Therapeutic Area Head of Neuroscience at The Janssen Pharmaceutical Companies of Johnson & Johnson, shared some of the promising developments in the neuroscience space, such...
View ArticleClik here to view.
Neuro drugs dumped by AbbVie are now heading to Neurocrine for $100M up front
AbbVie returned the rights to the drugs to Sosei Heptares earlier this year. Now Neurocrine Biosciences has agreed to pay the Japanese drug company $100 million to license the rights to these...
View ArticleClik here to view.
Sumitomo Schizophrenia Drug Discovered With AI Tech Fails in Two Phase 3 Trials
A schizophrenia drug candidate from partners Sumitomo Pharma and Otsuka Pharmaceutical failed to outperform a placebo in two Phase 3 studies. The compound is the most advanced program from a psychiatry...
View ArticleClik here to view.
AI-Generated Drug Candidates Are Here, But Clinical Trial Wins Need More Time
Despite artificial intelligence’s growing role in drug research, a fully AI-generated molecule has yet to advance from discovery all the way through clinical development. A novel molecule may...
View Article
